Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2026 09:54 ET | Source: Junshi Biosciences

Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates

Junshi Biosciences announced its financial results for the full year of 2025 and provided corporate updates.
March 09, 2026 09:00 ET | Source: Junshi Biosciences

Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications

NDAs for Toripalimab Injection (Subcutaneous) Across 12 Indications accepted by the NMPA
February 24, 2026 19:30 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)

Jointly evaluate the synergistic therapeutic potential of JS207 (PD-1/VEGF BsAb) and ATG-037 (oral small-molecule CD73 inhibitor)
December 05, 2025 22:11 ET | Source: Junshi Biosciences

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Promising long-term survival results from toripalimab's JUPITER-02 and JUPITER-06 presented at the ESMO ASIA
December 05, 2025 10:19 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

BLA of Roconkibart (IL-17A) for the treatment of moderate to severe plaque psoriasis has been accepted by the NMPA